THE IN VITRO EFFECT OF LYSOSTAPHIN ON CLINICAL ISOLATES OF STAPHYLOCOCCUS AUREUS

1964 ◽  
Vol 10 (6) ◽  
pp. 823-828 ◽  
Author(s):  
C. Bruce Cropp ◽  
Edward F. Harrison

Lysostaphin, an antibiotic that is unique inasmuch as it lyses all strains of Staphylococcus aureus, has been tested against 252 strains obtained from clinical sources. The clinical isolates were phage typed and tested for in vitro susceptibility to lysostaphin and seven other antistaphylococcal antibiotics.The resistant strains, found generally in phage groups I, III, and Insensitive, were most susceptible to vancomycin, lysostaphin, ristocetin, and kanamycin. The antibiotics least effective were penicillin G, tetracycline, phenethicillin, and erythromycin. As an attempt to quantitate the susceptibility of various clinical strains of 5.S. aureus to lysostaphin, a "lysostaphin index" was devised in which, by an arbitrary criterion, the susceptibility of a clinical isolate was related to the sensitivity of S. aureus, strain FDA 209P. It was found that all isolates were lysed by lysostaphin.

2010 ◽  
Vol 5 (6) ◽  
pp. 821-826
Author(s):  
Monika Staniszewska ◽  
Beata Rozbicka ◽  
Aleksandra Rajnisz ◽  
Ewa Bocian ◽  
Ewa Wasińska ◽  
...  

AbstractThe incidence of candidiasis among immunocompromised patients and emergence of antimycotics resistant strains has increased significantly. The aims of this study were: to examine the in vitro activity of antimycotics and biocides against Candida clinical isolates; to detect cross-resistance of fungi to these preparations and to estimate whether disinfectants applied in hospital areas are active against clinical Candida isolates. In vitro susceptibility of 102 Candida isolates to eight antimycotics was examined by Etest and ATB Fungus. Sensitivity of these strains to four disinfectants and an antiseptic agent was tested according to EN 1275:2005. Amphotericin B, caspofungin and 5-fluorocytosine were the most effective antimycotics against all Candida isolates. Resistance to itraconazole and fluconazole was observed among C. krusei and C. glabrata. The MICs (Minimal Inhibitory Concentrations) for ketoconazole, voriconazole and posaconazole against Candida albicans ranged: 0.003 - >32 μg/ml and one strain was resistant to three agents tested. All analysed Candida strains were sensitive to biocides containing either chlorine, aldehyde, alcohol mixtures, glucoprotamin or chlorhexidine gluconate with isopropanol. Sensitivity to these agents was observed at concentrations lower than those concentrations recommended by manufacturers to achieve proper biocidal activity to those preparations. Our data suggest that these disinfectants can be effectively applied in clinical wards to prevent nosocomial Candida infections.


2012 ◽  
Vol 56 (2) ◽  
pp. 139-143
Author(s):  
Magdalena Małkińska-Horodyska ◽  
Joanna Kubiak ◽  
Henryka Lassa ◽  
Edward Malinowski

Abstract The isolates of Staphylococcus aureus strains were examined phenotypically by cultural features, tube coagulase test and clumping factor (CF), and genotypically by conventional PCR. The strains had positive reaction in CF test, but were negative in tube coagulase test. The analysed strains from the same cows in each year expressed also nuc and coa genes. About 25% of the strains were examined by the disc diffusion method for their sensitivity to antibiotics. During three years, the strains were highly susceptible in vitro to amoxicillin with clavulanic acid, oxacillin, bacitracin, and cefoperazone (more than 90%), and highly resistant to tetracycline, neomycin, and streptomycin. Forty randomly chosen strains, and eight strains from the same cows in each year were analysed for minimal inhibitory concentration of penicillin G using microdilution method. An increasing resistance to the penicillin was noted. Moreover, eight strains, the same in each year, were also examined for β-lactamase production and methicillin resistance. No β-lactamase producers and no methicillin resistant strains were found using phenotypic and genotypic methods. In conclusion, it can be stated that antimicrobial susceptibility can change from one year to another.


1996 ◽  
Vol 42 (10) ◽  
pp. 1024-1031 ◽  
Author(s):  
David A. Hart ◽  
Carol Reno ◽  
Thomas Louie ◽  
Wallace Krulicki

Clinical isolates of Staphylococcus aureus were found to exhibit strain-specific heterogeneity to the growth-enhancing effects of human urokinase (UK), a proteinase with plasminogen activator activity. Nine out of fourteen (64%) methicillin-sensitive strains of S. aureus were responsive to UK in "in vitro" cultures. In contrast, 3/29 (10%) methicillin-resistant strains were responsive to the proteinase. When only strains isolated from western Canada were considered, 6/11 methicillin-sensitive strains and 1/26 methicillin-resistant strains were responsive to UK. The single western Canadian methicillin-resistant strain (strain 456) responsive to UK was one of two isolated from the same patient, indicating that the two strains were phenotypically different. Strain 456, resistant to 32 μg mefhicillin/mL, was responsive to as little as 50 U UK/mL and enhancement of growth was evident by 9 h of incubation at 37 °C. This growth enhancement was specific to UK and not duplicated by equivalent concentrations of other proteins (bovine serum albumin, trypsin, plasminogen). The results presented indicate differences in the frequency of the UK-responsive phenotype between methicillin-sensitive and -resistant S. aureus. These findings indicate that the UK phenotype of S. aureus may have utility in both phenotyping clinical isolates, as well as providing insights into the regulation of growth in this clinically important organism.Key words: Staphylococcus aureus, growth, urokinase, methicillin resistance.


2007 ◽  
Vol 51 (5) ◽  
pp. 1737-1740 ◽  
Author(s):  
A. J. O'Neill ◽  
F. McLaws ◽  
G. Kahlmeter ◽  
A. S. Henriksen ◽  
I. Chopra

ABSTRACT Resistance to fusidic acid in Staphylococcus aureus often results from acquisition of the fusB determinant or from mutations in the gene (fusA) that encodes the drug target (elongation factor G). We now report further studies on the genetic basis of resistance to this antibiotic in the staphylococci. Two staphylococcal genes that encode proteins exhibiting ca. 45% identity with FusB conferred resistance to fusidic acid in S. aureus. One of these genes (designated fusC) was subsequently detected in all fusidic acid-resistant clinical strains of S. aureus tested that did not carry fusB or mutations in fusA, and in strains of S. intermedius. The other gene (designated fusD) is carried by S. saprophyticus, explaining the inherent resistance of this species to fusidic acid. Fusidic acid-resistant strains of S. lugdunensis harbored fusB. Thus, resistance to fusidic acid in clinical isolates of S. aureus and other staphylococcal species frequently results from expression of FusB-type proteins.


PEDIATRICS ◽  
1975 ◽  
Vol 55 (1) ◽  
pp. 145-146
Author(s):  
Samuel Katz ◽  
Jerome O. Klein ◽  
Martha D. Yow ◽  
Fred F. Barrett ◽  
Roger S. Feldman ◽  
...  

Strains of Hemophilus influenzae type b highly resistant in vitro to ampicillin have been reported from several widely separated locations in the United States since December 1973.1-4 These strains were isolated from children with meningitis and the clinical course corroborated the in vitro susceptibility results. Until the importance of these resistant strains can be ascertained, hospital laboratories are urged to test clinical isolates of H. influenzae type b for susceptibility to ampicillin, and physicians must reconsider the treatment of patients with severe disease due to this organism. Ampicillin disk sensitivity tests of H. influenzae isolates are satisfactory for screening purposes but strains that are of equivocal sensitivity or are resistant should also be tested by a quantitative method, such as the tube dilution or agar diffusion techniques. The appropriate methods for antibiotic susceptibility tests were reviewed recently in a weekly report of the Center for Disease control.5 If facilities for these tests are unavailable or if confirmation of test results is desired, the bacterial strains may be forwarded, via the State Public Health Laboratory, to the Center for Disease Control. In areas where resistant strains have been recognized, initial therapy of children with documented or suspected severe infection due to H. infiuenzae type b, such as sepsis, meningitis, epiglottitis, arthritis, or cellulitis, should include an antimicrobial agent of known efficacy. Initial administration of penicillin G or ampicillin and chloramphenicol would seem appropriate at this time. The antimicrobial regimen should be reevaluated when the results of the bacterial isolation studies and antimicrobial sensitivity tests are available.


2019 ◽  
Vol 12 (3) ◽  
pp. 128
Author(s):  
Fernanda Gomes ◽  
Maria Rodrigues ◽  
Natália Martins ◽  
Isabel Ferreira ◽  
Mariana Henriques

Antibiotics are the elective drugs in bovine mastitis (BM) treatment, despite their low rates of efficiency and effectiveness and increasing risk of pathogen resistance. In this sense, it is urgent to discover new and effective antimicrobial agents to apply in BM control and even treatment. Plant extracts have been widely recognized as a rich source of phytochemicals with antimicrobial potential. Thus, the present work aims to compare the bioactivity of Eucalyptus globulus and Juglans regia extracts against Staphylococcus aureus bovine mastitis strains with penicillin G. At non-toxic concentrations, E. globulus exerted a bacteriostatic effect in planktonic cells and J. regia had no antimicrobial activity. Penicillin G, at minimum inhibitory concentration (MIC), demonstrated bactericidal activity, but just for S. aureus 3, 5, 6 and ATCC 25923, while the other strains seem to have acquired resistance. On the other hand, E. globulus and penicillin G in combination demonstrated synergy, being the most effective approach against S. aureus 1, 2 and 4. Thus, penicillin alone and in combination with E. globulus or J. regia seems to be promissory strategies to control bovine mastitis infections.


2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S726-S727
Author(s):  
Claudia Ramirez-Sanchez ◽  
Hedieh Attai ◽  
Daria Van Tyne ◽  
Ryan K Shields ◽  
Ortal Yerushalmy ◽  
...  

Abstract Background Staphylococcus aureus is a common cause of biofilm-mediated left ventricular device (LVAD) infections which are difficult to resolve with antibiotics alone and are associated with substantial morbidity and mortality. Recently, bacteriophages (phage) therapy has been used to resolve LVAD infections in a few cases. Our goal was to assess in vitro susceptibility and anti-biofilm activity of two S. aureus bacteriophages against clinical isolates from patients with S. aureus LVAD infections in order to develop a S. aureus phage cocktail for clinical use. Methods Two bacteriophages, OMS1 and OMS2, from the Israeli Phage Bank, were assessed for lytic activity against 15 S.aureus isolates (9 methicillin resistant, MRSA and 6 methicillin susceptible, MSSA) via agar overlay method and plaque forming units (PFU)/mL were enumerated. We then formed bacterial biofilms after overnight incubation at 120 rpm in a 96-well plates in duplicate; experiments were repeated thrice. Wells were then treated with tryptic soy broth (TSB, control) or TSB containing phage at 109 PFU/mL for 24 hours. After washing, biofilms were stained with crystal violet and biomass quantified via optical density at 570mm. Results All bacterial isolates were susceptible to both phages via agar overlay to varying degrees as determined by phage titers obtained via serial dilutions (Figure 1a, 1b). OMS1 led to significant reduction in biofilm of 7/9 MRSA and 3/6 MSSA isolates and OMS2 reduced biofilms in 9/9 MRSA and 4/6 MSSA isolates (Figure 1c). Phage titers and Biofilm Biomass Figure 1a) Phage titers in PFU/ml obtained from each bacterial isolate via agar overlay method. 1b) Representative agar plate demonstrating lytic plaques from OMS1 and OMS2 on a Staphylococcus aureus LVAD isolate. 1c) Biofilm biomass of Staphylococcus aureus isolates alone (SA) or with individual phage (SA+OMSA1 and SA=OMS2) assessed by optical density readings at 570 nm; error bars represent standard error of the mean. Conclusion We demonstrated in vitro lytic and anti-biofilm activity of 2 S. aureus phages against clinical S. aureus isolates from patients with LVAD infection. Our data suggests that phage susceptibility measured with agar overlay does not always correlate with phage susceptibility of S. aureus biofilms, suggesting that more than one method should be used to assess in vitro activity. We plan to assess for synergistic activity with the phage combination. Disclosures Ryan K. Shields, PharmD, MS, Shionogi (Consultant, Research Grant or Support) Ran Nir-Paz, MD, BiomX (Consultant)Technophage (Scientific Research Study Investigator, Advisor or Review Panel member) Saima Aslam, MD, MS, BioMx (Consultant)Cystic Fibrosis Foundation (Grant/Research Support)Gilead (Consultant)Johnson and Johnson (Consultant)Merck (Consultant)


Sign in / Sign up

Export Citation Format

Share Document